Fenofibrate Shows Promise in Slowing Diabetic Retinopathy Progression.

Despite significant advancements in diabetes management, the prevalence of diabetic retinal disease remains a major public health concern. Diabetic retinopathy remains one of the leading causes of vision loss among adults with diabetes. Because current treatments primarily focus on advanced stages of diabetic retinopathy, there is a critical need for cost-effective therapies that can intervene earlier in disease development. An article about the LENS (Lowering Events in Non-proliferative Retinopathy in Scotland) trial, published in this issue of NEJM Evidence, offers a promising approach using fenofibrate, a lipid-lowering medication, to reduce the progression of diabetic retinopathy. [ABSTRACT FROM AUTHOR]